Wednesday, October 14, 2026

Enterprise AI Platforms Hit Commercial Scale as Rezolve Processes 51 Billion API Calls

Rezolve Ai processed over 51 billion API calls in 2025 across its Brain Commerce platform, serving 650 enterprise clients globally. AI video generation costs have dropped 95%+ since 2024, from hundreds of dollars per minute to single digits, while production teams have shrunk from 50-100 people to fewer than 10.

Source Trace Score11 source documents11 with a live linkVerifiability: Strong
Enterprise AI Platforms Hit Commercial Scale as Rezolve Processes 51 Billion API Calls
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Rezolve Ai processed more than 51 billion API calls across its Brain Commerce platform in 2025, marking a shift from experimental AI deployments to production-scale enterprise infrastructure. The company now serves over 650 clients globally despite maintaining a market capitalization under $1 billion.

The economics of AI deployment have transformed dramatically. Video generation costs fell from several hundred dollars per minute in 2024 to single-digit dollars in 2026—a decline exceeding 95%. Four major platforms now dominate the AI video generation market, consolidating a previously fragmented field.

Workforce requirements have compressed alongside costs. Production capabilities that required 50-100 person teams two years ago now operate with fewer than 10 employees, according to Cuty AI's year-end analysis. This compression affects both technical implementation and creative production roles.

Rezolve's growth reflects enterprise buyers moving past pilot programs. The 51 billion API call volume represents sustained integration into customer-facing and internal business processes rather than proof-of-concept testing. The client expansion came through organic growth, partnerships, and strategic acquisitions rather than a single channel.

The technology is bifurcating into specialized domains. While general-purpose platforms achieve scale, AI applications are expanding into drug discovery, enterprise commerce, and vertical-specific use cases. This specialization follows the typical pattern of maturing technology markets—broad platforms coexist with focused solutions.

The sub-$1 billion valuation for Rezolve raises questions about market pricing of AI infrastructure companies. With 650 enterprise clients and 51 billion API calls processed, the company operates at a scale that typically commands higher valuations in cloud and SaaS markets.

Security and influence operation concerns are mounting as deployment scales. The same cost reductions and accessibility driving enterprise adoption also lower barriers for adversarial use cases, creating regulatory pressure around authentication and provenance.

The 95%+ cost decline in just two years mirrors historical patterns in cloud computing and mobile data, where Moore's Law dynamics and scale effects drove rapid price compression. Enterprise buyers now face procurement decisions based on production economics rather than experimental budgets.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score11 source documents11 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· February 9, 2026
    Cuty AI Announces the End of Tool Fragmentation with Unified AI Image and Video Creation
  2. [2]News articleYahoo Finance· December 16, 2025
    Rezolve Ai Shatters Year-End Expectations: December Revenue Expected to Exceed $17 Million, ARR Expected to Exceed $200 Million
  3. [3]News articleMIT Technology Review
    The scientist using AI to hunt for antibiotics just about everywhere
  4. [4]News articleYahoo Finance· January 18, 2026
    5 big analyst AI moves: Nvidia top 2026 pick, ASML gets big price target hike
  5. [5]Press releaseGlobeNewswire· February 26, 2026
    Large Language Model Market Forecasted to Reach USD 149.89 Billion by 2035 Driven by AI Automation and Open-Source Adoption
  6. [6]News articleNasdaq· February 25, 2026
    Stocks Settle Higher as AI Disruption Fears Ease
  7. [7]News articleYahoo Finance· February 25, 2026
    Tech stocks today: Nvidia stock rises as guidance signals AI boom alive and well
  8. [8]News articleYahoo Finance· February 24, 2026
    TELUS Digital showcases AI transformation in telecom: Unlocking value with innovative use cases at Mobile World Congress 2026
  9. [9]News articleMIT Technology Review
    The Download: how America lost its lead in the hunt for alien life, and ambitious battery claims
  10. [10]News articleYahoo Finance· February 26, 2026
    Top Research Reports for Meta, Netflix & Pfizer
  11. [11]News articleYahoo Finance· February 24, 2026
    Zillow Brings Home-Buying Help To Google's NotebookLM
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com